{"id":26395,"date":"2026-06-25T20:51:00","date_gmt":"2026-06-25T18:51:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=c0405478de77efe6018f44fc0676814b"},"modified":"2026-06-25T20:51:00","modified_gmt":"2026-06-25T18:51:00","slug":"imagion-biosystems-secures-au3-75m-in-capital-raise-following-fda-clearance-of-phase-2-clinical-trial","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=26395","title":{"rendered":"Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial"},"content":{"rendered":"

MELBOURNE, Australia--(BUSINESS WIRE)--$IBX<\/a> #FDA<\/a>--Imagion Biosystems, Ltd. (ASX: IBX)<\/a> announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA\u2019s clearance of the company\u2019s IND application<\/a> for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the MagSense\u00ae<\/a> imaging agent in HER2+ breast cancer. The company has already begun trial activation activities<\/a> and expects to begin patient recruitment later this year.<\/p><\/a><\/a>

\n\u201cWe are very pleased with the strong demand we saw from investors following our milestone achievement of receiving clearance from the FDA for our MagSense\u00ae imaging to proceed with the clinical trial,\u201d said Executive Chairman Robert Proulx<\/a>. \u201cThe successful submission of the IND represents a major technical and organizational accomplishment for the company. With this kind of shareholder support we can continue to advance our MagSense\u00ae molecular imaging technology and change how cancer is detected.\u201d<\/p>

\nThe raise was led by CPS Capital Group Pty Ltd<\/a> in a two-tranche placement with support from investors \u201cexceeding expectations.\u201d Tranche 1 will be a placement of 49.3 million new shares at AU$0.012 for a total of AU$592,000 utilizing the company\u2019s existing placement capacity. Tranche 2 will include the balance of shares, representing approximately AU$3.2 million, pending shareholder approval at an EGM.<\/p>

\nAbout MagSense\u00ae<\/b><\/p>

\nConventional MRI can identify regions of interest using anatomical or morphological features, but without molecular specificity, cannot reliably differentiate benign from malignant tumors. MagSense\u00ae uses targeted nanoparticles to increase imaging specificity, making it easier for clinicians to make cancer diagnoses with certainty. The platform technology\u2019s applications extend beyond breast cancer\u2014Imagion has conducted pre-clinical studies of two additional imaging agents that target prostate and ovarian cancers.<\/p>

\nAbout Imagion Biosystems<\/b><\/p>

\nImagion Biosystems (ASX: IBX) is a clinical-stage imaging company pioneering a new category of MRI technology that changes suspicion into certainty. The company has developed and is advancing clinical applications for MagSense\u00ae, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com<\/a>.<\/p> Contacts<\/b>

\nErich Boileau\nimagionbio@boileau.co<\/a><\/p>","protected":false},"excerpt":{"rendered":"

MELBOURNE, Australia–(BUSINESS WIRE)–$IBX #FDA–Imagion Biosystems, Ltd. (ASX: IBX) announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA\u2019s clearance of the company\u2019s IND application for a Phase 2 cli…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-26395","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/26395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26395"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/26395\/revisions"}],"predecessor-version":[{"id":26396,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/26395\/revisions\/26396"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}